scholarly journals C00006 PSYCHOLOGICAL IMPACT OF COVID 19 PANDEMIC ON PATIENTS WITH RHEUMATOLOGICAL DISORDERS - A WEB BASED CROSS-SECTIONAL MULTICENTRE SURVEY

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 216.3-216
Author(s):  
Y. G C ◽  
Y. P. Singh ◽  
S. Prasad ◽  
N. Srinivasulu ◽  
S. Kumar ◽  
...  
Keyword(s):  
Rheumatic Disease ◽  
Rheumatic Diseases ◽  
Educational Status ◽  
Anxiety Score ◽  
Beck Anxiety Inventory ◽  
Biological Drugs ◽  
Cross Sectional ◽  
Web Based ◽  
Autoimmune Rheumatic Diseases ◽  
Link Type

Background:The COVID-19 pandemic has resulted in uncertainty and negative psychological outcomes for patients with autoimmune rheumatic diseases for several reasons.1The anxiety is due to “underlying conditions” that are expected to increase the risk of infection and / or severe complications. Patients with rheumatological disorders fall into this group as they are believed to be immunosuppressed due to disease or the treatment. It is essential to understand the level of anxiety among the rheumatic disease patients at the current situation of COVID-19.Objectives:To study difference in Anxiety score (Mean/Avg Score) among following groups-underlying rheumatic disease, age, gender, marital status, educational status, employment status, medications, those who were on steroids/not, those who are Biologicals / Not.Methods:A web-based cross-sectional multi-centre survey was done across 5 rheumatology centres in India. The study duration was between 9th May and 16th May 2020.The questionnaire included consent, demographic details, medication history, opinion about tele rheumatology services and anxiety score measured by Beck Anxiety Inventory (BAI)2.Results:The survey was sent to 2987 patients, there were 933 responses and 581 were complete (Male =175). Complete responses were considered for data analysis. Most respondents were less than 50 years of age (70.6%). Rheumatoid arthritis (RA) was the most frequent (50.6%) diagnosis followed by other conditions. Most of the patients (43%) were on combination DMARD therapy, 12.7% of patients were on biological drugs and 23.9% of patients were on glucocorticoids. Statistically significant higher anxiety scores were observed in females, patients suffering from fibromyalgia, patients on glucocorticoids and biological agents. There was no difference in the anxiety scores with regard to age, educational status, and employment status.Difficulty in meeting rheumatologists and getting medications was expressed by 327 (56.2%) and 73 (29.7%) respondents respectively. Majority of respondents (86.6 %) agreed/strongly agreed regarding use of telemedicine to access health care during the crisis.Conclusion:The findings of the study revealed that anxiety is a major concern in patients with autoimmune rheumatic diseases. Fibromyalgia patients and those who were on glucocorticoids and biological drugs were found to have more anxiety levels compared to other groups of patients. In such periods of public health crises, telemedicine is a great tool for patients to access healthcare without fear of going to hospital. There is a need to intensify the awareness and address the mental health issues of rheumatology patients during this COVID-19 pandemic.References:[1]Pope, J.E. What Does the COVID-19 Pandemic Mean for Rheumatology Patients?. Curr Treat Options in Rheum (2020).https://doi.org/10.1007/s40674-020-00145-y.[2]Oh H, Park K, Yoon S, Kim Y, Lee SH, Choi YY, et al. Clinical utility of beck anxiety inventory in clinical and nonclinical Korean samples. Front Psychiatry.2018;9:666.https://doi.org/10.3389/fpsyt.2018.00666Disclosure of Interests:None declared

scholarly journals OP0265-HPR IMPACT OF COVID-19 PANDEMIC ON RHEUMATOLOGY PATIENTS IN NORTHERN IRELAND – A WEB BASED CROSS-SECTIONAL SURVEY

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 161.2-162
Author(s):  
P. McKee ◽  
A. Irvine ◽  
C. Riddell ◽  
E. Ball
Keyword(s):  
Northern Ireland ◽  
Rheumatic Disease ◽  
Rheumatic Diseases ◽  
Negative Impact ◽  
Tertiary Care ◽  
Cross Sectional Survey ◽  
Biological Drugs ◽  
Cross Sectional ◽  
Web Based ◽  
The Impact

Background:Concern for the susceptibility of rheumatology patients to severe COVID-19 illness has been raised since the start of the pandemic. Rheumatic disease and their immunosuppressant therapies placed many patients into the ‘clinically extremely vulnerable’ group when the UK’s shielding guidance commenced on 23 March 2020. The impact of DMARDs/glucocorticoids/biologics on COVID-19 remains under investigation 1. A recent study suggested caution may be required with rituximab and sulfasalazine in COVID-19 patients 2.Objectives:The objective of this study is to evaluate the impact of the COVID-19 pandemic on rheumatology patients in Northern Ireland by assessing demographics, rheumatic disease, medications, disease progress, shielding advice, access to primary & tertiary care and incidence of COVID-19 infection.Methods:A web-based cross-sectional survey was completed in Northern Ireland. The study duration was between 23rd November 2020 and 22nd January 2021. The questionnaire included consent, demographic details, medication history, comorbidities, disease course, patient experience, shielding advice, COVID-19 illness and hospitalisation. The survey was publicised by sending 6,032 Belfast Trust NHS patients a link via SMS, posters were displayed in rheumatology departments, and links made available via NHS/Versus Arthritis social media platforms.Results:There were 2,615 responses and of these 2,539 had been completed and were analysed. Most respondents were aged 45+ (78.27%) and female (N=1819). Rheumatoid arthritis (41%) and psoriatic arthritis (29%) were the most common diagnoses. Just over one third (35.27%, N=896) of patients were on biological drugs. Most patients were taking methotrexate (28.04%) followed by hydroxychloroquine (15.20%) and adalimumab (12.52%). The majority (79.6%) continued treatment during the pandemic. There was evidence of disease ‘flaring’ in 30.75% of patients who had stopped treatment. Of the respondents surveyed 7.8% (N=198), tested positive for Covid-19 and of these 77.55% reported that they had received adequate shielding advice, primarily from GP or UK government sources. Only 11.11% (N=22) of those who tested positive for Covid-19 required hospital admission and 2 patients required intensive care support. Both patients requiring ICU were not on immunosuppression. Less than one third of patients testing positive for COVID-19 were on biological drugs (30.3%, N=60). Cardiovascular disease was the most prevalent comorbidity. Of the 22 patients hospitalised with COVID-19, 13.64% (N=3) were on solitary sulphasalazine therapy.Conclusion:The survey showed low levels of COVID-19 hospitalisation despite most patients continuing DMARD/biologic/glucocorticoid therapy. This has been replicated in other studies 1, however data continues to be gathered on the safety of some biologic drugs particularly rituximab 2. Most of our patients received clear understandable shielding guidance from a variety of sources. Many patients expressed fear of mortality, isolation and mental health issues. The survey findings indicated that stopping medication can have a negative impact on disease control.References:[1]Robinson PC, Yazdany J. The COVID-19 Global Rheumatology Alliance: collecting data in a pandemic. Nat Rev Rheumatol. 2020 Jun;16(6):293-294.[2]Strangfeld A, Schäfer M, Gianfrancesco MA, et al. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Annals of the Rheumatic Diseases Published Online First: 27 January 2021. doi: 10.1136/annrheumdis-2020-219498Disclosure of Interests:None declared

scholarly journals The Effect of Obesity and Other Factors towards On the Increased Risk of Rheumatism in Indonesia (Analysis of IFLS 2014)

2021 ◽  
Vol 12 (1) ◽  
pp. 77-87
Author(s):  
Nuraini Nuraini ◽  
Amrina Rosyada
Keyword(s):  
Rheumatic Disease ◽  
Rheumatic Diseases ◽  
Cross Sectional Study ◽  
Sample Survey ◽  
Healthy Lifestyles ◽  
Sectional Study ◽  
Cross Sectional ◽  
Increased Risk ◽  
Gender Education ◽  
Complex Sample

The number of people with rheumatism worldwide has reached 355 million, and this is estimated by 2025, suggesting that more than 25% will experience paralysis. This study aims to determine obesity and other factors related to the increased risk of rheumatic diseases in Indonesia, the method used was data analysis using a complex sample survey. It used 2014 IFLS data and a cross sectional study design, as well as a multistage random sampling with a total of 29,106 respondents, and the results showed that the prevalence of rheumatic disease in Indonesia was 5.2% in 2014. The most dominant and unmodifiable variable that influenced incidence was gender (PR=1.686; 95% CI=1.488-1.910). Meanwhile, obesity is the most dominant and modifying variable that influences the incidence of rheumatic disease (PR=1.630; 95% CI=1.433-1.855). Factors that are simultaneously related to the increased risk of rheumatic diseases include age, gender, education, physical activity, protein consumption, obesity, and accident history. Considering the results, patients need to eat healthy and low purine foods, as well as implementing other healthy lifestyles such as appropriate, adequate, and regular physical activities in order to reduce the risk of rheumatism.

scholarly journals Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study

2021 ◽  
Author(s):  
Jorge Antonio Esquivel-Valerio ◽  
Cassandra Michele Skinner-Taylor ◽  
Ilse Andrea Moreno-Arquieta ◽  
Jesus Alberto Cardenas-de la Garza ◽  
Gisela Garcia-Arellano ◽  
...  
Keyword(s):  
Adverse Events ◽  
Rheumatic Diseases ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Cross Sectional ◽  
Autoimmune Rheumatic Diseases

scholarly journals Prevalence of thyroid autoantibodies in patients with systematic autoimmune rheumatic diseases. Cross-sectional study

2017 ◽  
Vol 135 (6) ◽  
pp. 535-540 ◽  
Author(s):  
Rayana Taques Posselt ◽  
Vinícius Nicolelli Coelho ◽  
Danieli Cristina Pigozzo ◽  
Marcela Idalia Guerrer ◽  
Marília da Cruz Fagundes ◽  
...  
Keyword(s):  
Rheumatic Diseases ◽  
Cross Sectional Study ◽  
Thyroid Autoantibodies ◽  
Sectional Study ◽  
Cross Sectional ◽  
Autoimmune Rheumatic Diseases

The Accuracy of Administrative Data Diagnoses of Systemic Autoimmune Rheumatic Diseases

2011 ◽  
Vol 38 (8) ◽  
pp. 1612-1616 ◽  
Author(s):  
SASHA BERNATSKY ◽  
TINA LINEHAN ◽  
JOHN G. HANLY
Keyword(s):  
Rheumatic Disease ◽  
Administrative Data ◽  
Rheumatic Diseases ◽  
Lupus Erythematosus ◽  
Population Based ◽  
Administrative Database ◽  
Case Definitions ◽  
Autoimmune Rheumatic Diseases ◽  
Specificity And Sensitivity ◽  
Clinical Records

Objective.To examine the validity of case definitions for systemic autoimmune rheumatic diseases [SARD; systemic lupus erythematosus (SLE), systemic sclerosis (SSc), myositis, Sjögren’s syndrome, vasculitis, and polymyalgia rheumatica] based on administrative data, compared to rheumatology records.Methods.A list of rheumatic disease diagnoses was generated from population-based administrative billing and hospitalization databases. Subjects who had been seen by an arthritis center rheumatologist were identified, and the medical records reviewed.Results.We found that 844 Nova Scotia residents had a diagnosis of one of the rheumatic diseases of interest, based on administrative data, and had had ≥ 1 rheumatology assessment at a provincial arthritis center. Charts were available on 824 subjects, some of whom had been identified in the administrative database with > 1 diagnosis. Thus a total of 1136 diagnoses were available for verification against clinical records. Of the 824 subjects, 680 (83%) had their administrative database diagnoses confirmed on chart review. The majority of subjects who were “false-positive” for a given rheumatic disease on administrative data had a true diagnosis of a similar rheumatic disease. Most sensitivity estimates for specific administrative data-based case definitions were > 90%, although for SSc, the sensitivity was 80.5%. The specificity estimates were also > 90%, except for SLE, where the specificity was 72.5%.Conclusion.Although health administrative data may be a valid resource, there are potential problems regarding the specificity and sensitivity of case definitions, which should be kept in mind for future studies.

scholarly journals Human Endogenous Retroviruses (HERVs) and Autoimmune Rheumatic Disease: Is There a Link?

2013 ◽  
Vol 7 (1) ◽  
pp. 13-21 ◽  
Author(s):  
Nicola Tugnet ◽  
Paul Rylance ◽  
Denise Roden ◽  
Malgorzata Trela ◽  
Paul Nelson
Keyword(s):  
Rheumatic Disease ◽  
Rheumatic Diseases ◽  
Chronic Conditions ◽  
Molecular Mimicry ◽  
Endogenous Retroviruses ◽  
Clinical Implications ◽  
Human Endogenous Retroviruses ◽  
Novel Treatments ◽  
Autoimmune Rheumatic Diseases ◽  
Autoimmune Rheumatic Disease

Autoimmune rheumatic diseases, such as RA and SLE, are caused by genetic, hormonal and environmental factors. Human Endogenous Retroviruses (HERVs) may be triggers of autoimmune rheumatic disease. HERVs are fossil viruses that began to be integrated into the human genome some 30-40 million years ago and now make up 8% of the genome. Evidence suggests HERVs may cause RA and SLE, among other rheumatic diseases. The key mechanisms by which HERVS are postulated to cause disease include molecular mimicry and immune dysregulation. Identification of HERVs in RA and SLE could lead to novel treatments for these chronic conditions. This review summarises the evidence for HERVs as contributors to autoimmune rheumatic disease and the clinical implications and mechanisms of pathogenesis are discussed.

scholarly journals COVID-19 in rheumatic diseases: A random cross-sectional telephonic survey

2020 ◽  
Author(s):  
Uma Kumar ◽  
Rudra Prosad Goswami ◽  
Danveer Bhadu ◽  
Maumita Kanjilal ◽  
Sandeep Nagar ◽  
...  
Keyword(s):  
Rheumatic Disease ◽  
Rheumatic Diseases ◽  
Lupus Erythematosus ◽  
Uneventful Recovery ◽  
Data Repository ◽  
New Delhi ◽  
National Capital Region ◽  
Cross Sectional ◽  
Infectious Episode ◽  
Government Data

Objective. To describe the incidence, clinical course, and predictive factors of coronavirus 2019 (COVID-19) infection in a cohort of rheumatological patients residing in New Delhi (National Capital Region), India. Methods. We performed a cross-sectional, random telephonic survey from 20th April to 20th July 2020 on patients with rheumatic diseases. Patients were interviewed with a predesigned questionnaire. The incidence of COVID‐19 in the general population was obtained from open access government data repository. Report of reverse transcriptase polymerase chain reaction report was taken as confirmatory of COVID-19 infection. Results. Among the 900 contacted patients 840 responded (713 with rheumatoid arthritis (RA), 100 with systemic lupus erythematosus (SLE), 20 with spondylarthritis (SpA) and 7 with others; mean age 45 years, mean duration 11.3 years; 86% female). Among them 29 reported flu-like symptoms and four RA patients had confirmed COVID-19 infection. All of them were hospitalized with uneventful recovery. Rheumatological drugs were discontinued during the infectious episode. Disease modifying agents and biologics were equally received by those with or without COVID-19. The incidence of COVID-19 was similar to general Delhi population (0.476% vs 0.519% respectively, p=0.86). Two patients had relapse of rheumatic disease after recovery. After recovery from COVID-19 or Flu-like illness, eight patients (27.6%, 95% confidence interval 14.7-45.7) reported disease flare. Conclusion. Patients with rheumatic diseases in India have similar incidence of COVID-19 infection compared to the community. Relapse of underlying rheumatic disease after recovery is not uncommon and continuation of glucocorticoid through the infection should be considered.

scholarly journals Rheumatic Disease Among Oklahoma Tribal Populations: A Cross-sectional Study

2012 ◽  
Vol 39 (10) ◽  
pp. 1934-1941 ◽  
Author(s):  
JASMINE R. GADDY ◽  
EVAN S. VISTA ◽  
JULIE M. ROBERTSON ◽  
AMY B. DEDEKE ◽  
VIRGINIA C. ROBERTS ◽  
...  
Keyword(s):  
Rheumatic Disease ◽  
American Indian ◽  
Rheumatic Diseases ◽  
Lupus Erythematosus ◽  
Cross Sectional Study ◽  
Anticardiolipin Antibodies ◽  
Cross Sectional ◽  
American College Of Rheumatology ◽  
Tribal Populations ◽  
The Difference

Objective.Rheumatic diseases cause significant morbidity within American Indian populations. Clinical disease presentations, as well as historically associated autoantibodies, are not always useful in making a rapid diagnosis or assessing prognosis. The purpose of our study was to identify autoantibody associations among Oklahoma tribal populations with rheumatic disease.Methods.Oklahoma tribal members (110 patients with rheumatic disease and 110 controls) were enrolled at tribal-based clinics. Patients with rheumatic disease (suspected or confirmed diagnosis) were assessed by a rheumatologist for clinical features, disease criteria, and activity measures. Blood samples were collected and tested for common rheumatic disease autoantibodies [antinuclear antibody (ANA), anti-cyclic citrullinated peptide antibodies (anti-CCP), rheumatoid factor (RF), anti-Ro, anti-La, anti-Sm, anti-nRNP, anti-ribosomal P, anti-dsDNA, and anticardiolipins].Results.In patients with suspected systemic rheumatic diseases, 72% satisfied American College of Rheumatology classification criteria: 40 (36%) had rheumatoid arthritis (RA), 16 (15%) systemic lupus erythematosus, 8 (7%) scleroderma, 8 (7%) osteoarthritis, 4 (4%) fibromyalgia, 2 (2%) seronegative spondyloarthropathy, 1 Sjögren’s syndrome, and 1 sarcoidosis. Compared to controls, RA patient sera were more likely to contain anti-CCP (55% vs 2%; p < 0.001) or RF IgM antibodies (57% vs 10%; p < 0.001); however, the difference was greater for anti-CCP. Anti-CCP positivity conferred higher disease activity scores (DAS28 5.6 vs 4.45; p = 0.021) while RF positivity did not (DAS28 5.36 vs 4.64; p = 0.15). Anticardiolipin antibodies (25% of rheumatic disease patients vs 10% of controls; p = 0.0022) and ANA (63% vs 21%; p < 0.0001) were more common in rheumatic disease patients.Conclusion.Anti-CCP may serve as a more specific RA biomarker in American Indian patients, while the clinical significance of increased frequency of anticardiolipin antibodies needs further evaluation.

Sign in / Sign up

Export Citation Format

Share Document